Literature DB >> 29501808

Will Biomarkers Succeed as a Surrogate Endpoint in Heart Failure Trials?

James L Januzzi1.   

Abstract

Entities:  

Keywords:  biomarker; heart failure; outcomes

Mesh：

Substances：

Year:  2018        PMID： 29501808     DOI： 10.1016/j.jchf.2018.02.008

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN： 2213-1779            Impact factor:   12.035


× No keyword cloud information.
  4 in total

1.  The Utility of Circulating and Imaging Biomarkers Alone and in Combination in Heart Failure.

Authors:  Biyanka Jaltotage; Girish Dwivedi; Daryl Eng Lee Ooi; Gnanadevan Mahadavan
Journal:  Curr Cardiol Rev       Date:  2021

2.  Association of Repetitive Dosing of Levosimendan with Reduction of NYHA Class and NT-proBNP Levels in Decompensated Heart Failure: A Retrospective Cohort Study.

Authors:  Maximilian Wechsler; Robert H G Schwinger
Journal:  Drugs Real World Outcomes       Date:  2022-07-06

3.  Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.

Authors:  Atsushi Tanaka; Shigeru Toyoda; Takumi Imai; Kazuki Shiina; Hirofumi Tomiyama; Yasushi Matsuzawa; Takahiro Okumura; Yumiko Kanzaki; Katsuya Onishi; Arihiro Kiyosue; Masami Nishino; Yasushi Sakata; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2021-09-03       Impact factor: 9.951

4.  Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.

Authors:  Kenya Kusunose; Takumi Imai; Atsushi Tanaka; Kaoru Dohi; Kazuki Shiina; Takahisa Yamada; Keisuke Kida; Kazuo Eguchi; Hiroki Teragawa; Yasuchika Takeishi; Nobuyuki Ohte; Hirotsugu Yamada; Masataka Sata; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2021-09-14       Impact factor: 9.951
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.